"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MORE
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLES
Whilst we typically view the pharmaceutical industry through medicines sales and volume, patient-centred metrics are ultimately crucial for a fully comprehensive understanding of the market. IQVIA's new MIDAS Patient data estimates the number of patients taking medicines, and offers both granular segmentation and scale. Estimated patient numbers provide a valuable new angle to analysis of the competitive landscape, particularly as the industry becomes increasingly multi-indicational and complex, and also bring a different perspective to medicines access, adding nuance that was previously lost in discussions about dollars and packs.
In this blog, we investigate key trends and drivers in the number of patients treated with prescription medicines across major disease areas, using MIDAS Patient.
Respiratory conditions account for more drug-treated patients globally than any other therapy area, as seen in Figure 1. This significant lead is driven by highly prevalent diseases and conditions such as the common cold, influenza, allergic rhinitis, tonsilitis and asthma. Many of these are acute and require short-term treatment courses, resulting in a high number of treated patients relative to medicine volume. Some individuals may even take prescription medicines for multiple colds and allergic flare-ups within a year. Within the respiratory area, acute upper respiratory infections and allergic rhinitis together constitute over 40% of all drug-treated patients and nearly 30% of total volume (standard units), and these patients are most commonly treated with corticosteroids, antibiotics, and antihistamines.
While Cardiovascular is the leading disease area by volume, it accounts for a relatively low number of drug-treated patients. Hypertension is the leading cardiovascular disease, accounting for over 60% of drug-treated patients and 70% of treatment standard units. Therefore, in contrast to Respiratory, the Cardiovascular disease area is dominated by a single condition and treatment type (antihypertensives). Additionally, the majority of cardiovascular diseases are chronic in nature, such as hypertension and heart disease, culminating in a lower overall treated patient population relative to medicine volume.
Each therapy area also exhibits unique dynamics over time, in terms of drug-treated patient numbers: for example, Oncology has grown fastest over the last 5 years, with a CAGR of 4% (2019 – 2024). This high growth rate has largely been driven by patients treated for liver cancer and haematological cancers. Overall, oncology accounts for notably few drug-treated patients compared to other major therapy areas, especially given that it is the leading therapy area in terms of total prescription medicine sales1. However, many oncology therapies are highly innovative and high-value, and MIDAS Patient data reveals that they are reaching a steadily growing number of patients.
For a deeper dive into these topics, register to access the webinar—live or on demand at your convenience. Explore global market dynamics, treated patient trends in Oncology, Immunology, and Obesity, along with global health insights on antibiotic use and resistance.
1IQVIA Early Bird: Pharma Defining Trends in 2024 and What Lies Ahead - IQVIA
IQVIA MIDAS® has long been considered the industry benchmark for global market measurement, integrating the breadth and depth of IQVIA's unparalleled data assets with advanced analytics and deep domain expertise across 95 countries.
Just launched, MIDAS Patient adds patient insights across 600 diseases at scale to evolve with industry transformation towards multi-indication drugs and ensuring patient-centricity at the forefront. Life sciences organizations can now easily make disease comparisons supported by patient metrics across the MIDAS universe.
Analyze industry leading sales and medical data in a standardized and comparable way, including cross-country analysis of performance and additional insights into global and regional markets.
Measure the performance of your sales force and marketing channels, adapt your commercial strategy and gain real world competitive insights.
